Controversial issues in adjuvant systemic therapy of early breast cancer

Acta Oncologica

Volumn 37, Issue 5, 1998, Pages 421-430

  Rutqvist, Lars E ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; TAMOXIFEN; TAXANE DERIVATIVE;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DNA ADDUCT; DRUG DOSE; ENDOMETRIUM CANCER; FEMALE; GENOTOXICITY; HIGH RISK POPULATION; HUMAN; HYPOTHESIS; LEUKEMIA; LONG TERM CARE; MEDICAL DECISION MAKING; META ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME;

ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; BRIDGED COMPOUNDS; CASTRATION; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; FEMALE; HUMANS; LEUKEMIA; PROGNOSIS; TAMOXIFEN; TAXOIDS;

EID: 0031790814     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/028418698430368     Document Type: Review

References (60)

1. Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who received adjuvant chemotherapy. N Engl J Med 1997; 337: 949-55.
2. Ragaz J, Jackson SM, Le N, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 1997; 337: 956-62.
3. Greenberg PAC, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14: 2197-205.
4. Early Breast Cancer Trialists' Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomized trials among 28896 women. N Engl J Med 1988; 319: 1681-92.
5. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Treatment of early breast cancer: worldwide evidence in 1985 1990. A systematic overview of all available randomized trials in early breast cancer of adjuvant endocrine and cytotoxic therapy. Treatment of Early Breast Cancer, Vol. I. London: Oxford University Press, 1990.
6. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992; 339: 1-15, 71-85.
7. Early Breast Cancer Trialists' Collaborative Group. Effects of radiotherapy and surgery in early breast cancer. N Engl J Med 1995; 333: 1444-55.
8. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Submitted, 1998.
9. Fisher B, Carbone P, Economou S, et al. L-phenylalanine mustard (L-PAM) in the management of primary breast cancer. N Engl J Med 1975; 292: 117-21.
10. Bonadonna G, Brusamolino E, Valagussa P, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976; 294: 405-19.
11. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate and fluorouracil in node positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995; 332: 901-6.
12. Padmanabhan N, Howell T, Rubens RD. Mechanism of action of adjuvant chemotherapy in early breast cancer. Lancet 1986; ii: 411-4.
13. Bonadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 1981; 304: 10-5.
14. Gelber R, Goldhirsch A. A new end-point for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. J Clin Oncol 1986; 4: 1772-9.
15. Levine M, Bramwell V, Bowman D, et al. A clinical trial of intensive FEC versus CMF in premenopausal women with node-positive breast cancer. Proc Am Soc Clin Oncol 1995; 14: 112a.
16. National Institutes of Health Breast Cancer Chemotherapy Consensus Conference. Adjuvant chemotherapy for breast cancer. JAMA 1985; 254: 3461-3.
17. Tallman MS, Gray R, Bennett JM, et al. Leukomogenic potential of adjuvant chemotherapy for early-stage breast cancer: the Eastern Cooperative Oncology Group experience. J Clin Oncol 1995; 13: 1557-63.
18. Diamandidou E, Buzdar AU, Smith TL, Frye D, Witjaksono M, Hortobagyi GN. Treatment-related leukemia in breast cancer patients treated with fiuorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: the University of Texas M D Andersson Cancer Center experience. J Clin Oncol 1996; 14: 2722-30.
19. Fisher B, Anderson S, Wickerham DL, et al. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 1997; 15: 1858-69.
20. Hryniuk WM. The importance of dose intensity in the outcome of chemotherapy. Imp Adv Oncol 1988; 121-141.
21. Tannock IF, Boyd NF, DeBoer G, et al. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast disease. J Clin Oncol 1988; 6: 1377-87.
22. Engelsman E, Klijn JCM, Rubens RD, et al. 'Classical' CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. Eur J Cancer 1991; 27: 966-70.
23. Wood WC, Budman DR, Korzun AH, et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinomas. N Engl J Med 1994; 330: 1253-9.
24. Hortobagyi GN, Bodey GP, Buzdar AU, et al. Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units. A prospective randomized study. J Clin Oncol 1987; 5: 354-64.
25. Dimitrov N, Anderson S, Fisher B. Dose intensification and increased total dose of adjuvant chemotherapy for breast cancer (BC): findings from NSABP B-22. Proc Am Soc Clin Oncol 1994; 13: 64 (abstr).
26. Bezwoda WR, Seymour L, Dansey RD. High-dose chemotherapy with hematopoetic rescue as primary treatment for metastatic breast cancer. A randomized trial. J Clin Oncol 1995: 13: 2483-9.
27. Peters WP, Jones RB, Vredenburgh J, et al. A large, prospective, randomized trial of high-dose combination alkylating agents (CPB) with autologous vellular support (ABMS) as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction chemotherapy (AFM). Proc Am Soc Clin Oncol 1996; 15: 121.
28. Savarese DM, Hsieh C, Stewart FM. Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumors. J Clin Oncol 1997; 15: 2981-95.
29. Siu LL, Tannock IF. Chemotherapy dose escalation: case unproven (Editorial). J Clin Oncol 1997; 15: 2765-8.
30. Bonadonna G, Zambetti M, Valagussa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes: ten-year results. JAMA 1995; 273: 542-7.
31. Gundersen S, Kvinnsland S, Lundgren S, et al. Cyclical use of tamoxifen and high-dose medroxyprogesterone acetate in advanced estrogen receptor positive breast cancer. In: Paterson HG, Lees AW, eds. Fundamental problems in breast cancer. Boston: Martinus Nijhoff, 1987: 187-91.
32. Rutqvist LE. Randomized adjuvant breast cancer trials in Sweden. Cancer 1994; 74: 1156-9.
33. Nissen-Meyer R, Höst H, Kjellfren K, et al. Treatment of node-negative breast cancer with short course of chemotherapy immediately after surgery. NCI Monogr 1986; 1: 125-8.
34. Abram WP, Baum M, Berstock DA, et al. Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer. Preliminary analysis by the CRC Adjuvant Breast Trial Working Party. Br J Cancer 1988: 57: 604-7.
35. Ludwig Breast Cancer Study Group. Combination adjuvant chemotherapy for node-positive breast cancer. Inadequacy of a single perioperative cycle. N Engl J Med 1988; 319: 677-83.
36. Clahsen PC, van de Velde C, Goldhirsch A, et al. An overview of randomized perioperative polychemotherapy trials in women with early breast cancer. J Clin Oncol. in press.
37. Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy in local-regional disease in women with operable breast cancer: findings from the National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997; 15: 2483-93.
38. Skoog L, Rutqvist LE, Wilking N. Analysis of hormone receptors and proliferating fraction in fine-needle aspirates from primary breast carcinomas during chemotherapy or tamoxifen treatment. Acta Oncol 1992; 31: 139-41.
39. Rowinsky EK. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med 1997; 48: 353-74.
40. Paterson R, Russel M H. Clinical trials in malignant disease: part II. Breast cancer: value of irradiation of the ovaries. J Fac Radiol 1959; 10: 130-3.
41. Early Breast Cancer Trialists' Collaborative Group. Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet 1996; 348: 1189-96.
42. Osborne CK. Effects of estrogens and antiestrogens on cell proliferation: implications for the treatment of breast cancer. Cancer Treat Res 1988; 39: 11-129.
43. Osborne CK, Kitten L, Arteaga CL. Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens. J Clin Oncol 1989; 7: 710-7.
44. Swedish Breast Cancer Cooperative Group. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst 1996; 88: 1543-9.
45. Current Trials Working Party of the Cancer Research Campaign Breast Cancer Trials Group. Preliminary results from the Cancer Research Campaign Trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer. J Natl Cancer Inst 1996; 88: 1834-9.
46. Fisher B, Dignam J, Bryant J, et al. The worth of five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996; 88: 1529-42.
47. Stewart HJ, Forrest AP, Everington D, et al. Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group. Br J Cancer 1996; 74: 297-9.
48. Rossner S, Wallgren A. Serum lipoproteins and proteins after breast cancer surgery and effects of tamoxifen. Atherosclerosis 1984; 52: 339-46.
49. McDonald CC, Stewart HJ. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial: the Scottish Breast Cancer Committee. Br Med J 1991; 303: 435-7.
50. Rutqvist LE, Mattsson A. Cardiac and thrombembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. J Natl Cancer Inst 1993; 85: 1398-406.
51. Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992; 326: 852-6.
52. McDonald CC, Alexander FE, Whyte BW, Forrest AP, Stewart HJ. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trials Breast Group. Br Med J 1995; 311: 977-80.
53. Magriples U, Naftolin F, Schwartz PE, Carcangiu ML. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 1993; 11: 485-90.
54. Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornander T, Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Natl Cancer Inst 1995; 87: 645-51.
55. Han X, Liehr J. Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res 1992; 52: 1360-3.
56. Sigurdsson H, Baldetorp B, Borg A, et al. Indicators of prognosis in node-negative breast cancer. N Lngl J Med 1990; 322: 1045-53.
57. Rutqvist LE, Cedermark B, Fornander T, et al. The relationship between hormone receptor content and the effect of adjuvant tamoxifen in operable breast cancer. J Clin Oncol 1989; 7: 1474-84.
58. Stål O, Skoog L, Rutqvist LE, et al. S-phase fraction and survival benefit from adjuvant chemotherapy or radiotherapy of breast cancer. Br J Cancer 1994; 70: 1258-62.
59. Muss HB, Thor AD, Berry DA, et al. C-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994; 330: 1260-6.
60. Gasparini G, Barbareschi M, Doglioni C, et al. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin Cancer Res 1995; 1: 189-98.